ArticleBreast cancer research : BCR2009
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
Article in Breast cancer research : BCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 240 citations in OpenAlex.
- Trial
- Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients.Journal of the American College of Surgeons · 2016Trial
- Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.PloS one · 2013Trial
- Characterizing epithelial-mesenchymal transition-linked heterogeneity in breast cancer circulating tumor cells at a single-cell level.Molecular oncology · 2025Article
- Liquid biopsy: paving a new avenue for cancer research.Cell adhesion & migration · 2024Review
- Review
- An Image-Based Identification of Aggressive Breast Cancer Circulating Tumor Cell Subtypes.Cancers · 2023Article
- Article
- Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™-HER2-FISH workflow.Breast cancer (Tokyo, Japan) · 2022Article
- Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer.Frontiers in cell and developmental biology · 2022Review
- Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.Cancers · 2021Article
- Article
- Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway.Oncogene · 2021Article
- RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy.Therapeutic advances in medical oncology · 2021Article
- Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.Journal of cellular and molecular medicine · 2020Article
- AMPK Activation by Metformin Promotes Survival of Dormant ERClinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- HER2-targeted therapy influences CTC status in metastatic breast cancer.Breast cancer research and treatment · 2020Article
- The Different Facets of Liquid Biopsy: A Kaleidoscopic View.Cold Spring Harbor perspectives in medicine · 2020Review
- Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer.Cancers · 2020Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe role of circulating tumor cells (CTCs) in blood of primary breast cancer patients is still under investigation. We evaluated the incidence of CTCs in blood, we evaluated the correlation between CTCs and disseminated tumor cells (DTCs) in the bone marrow (BM), and we characterized CTCs for the expression of HER2, the estrogen receptor (ER) and the progesterone receptor (PR).
methodsBlood of 431 patients with primary breast cancer were analyzed for EpCAM, MUC1 and HER2 transcripts with the AdnaTest BreastCancer (AdnaGen AG, Germany). Expression of the ER and PR was assessed in an additional RT-PCR. BM aspirates from 414 patients were analyzed for DTCs by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.
resultsDTCs were found in 107/414 patients (24%), CTCs were detected in 58/431 (13%) patients. DTCs were associated with PR status of the primary tumor (P = 0.04) and CTCs significantly correlated with nodal status (P = 0.04), ER (P = 0.05), and PR (P = 0.01). DTCs in the BM weakly correlated with CTCs (P = 0.05) in blood. Interestingly, the spread of CTCs was mostly found in triple-negative tumors (P = 0.01) and CTCs in general were mostly found to be triple-negative regardless of the ER, PR and HER2 status of the primary tumor.
conclusions(1) Due to the weak concordance between CTCs and DTCs the clinical relevance may be different. (2) The biology of the primary tumor seems to direct the spread of CTCs. (3) Since the expression profile between CTCs and the primary tumor differs, the consequence for the selection of adjuvant treatment has to be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.